Answers are grounded in this paper and cite their sources.
resistance has been reported, and acquired resistance is inevitable for most patients over time, leading to relapsed/refractory disease and poor outcomes. Sustained protein synthesis coupled with impaired/insufficient proteolytic mechanisms makes MM cells exquisitely sensitive to perturbations in protein homeostasis, offering us the opportunity to target this intrinsic vulnerability for therapeutic purposes. This review highlights the scientific rationale for the clinical use of FDA-approved and investigational agents targeting protein homeostasis in MM.
No takes yet. Share an insight, caveat, or question.
Moscvin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: